Prescriber Scope of Practice for ADHD in Pennsylvania

You’ve spent years training to treat ADHD. You know the diagnosis criteria, the medication protocols, the follow-up care. But now there’s another question keeping you from scaling your practice: Can I legally prescribe Adderall via telehealth in [your state]?

If you’re a psychiatrist, PMHNP, or prescriber considering telehealth for ADHD care, this isn’t an academic question—it’s the difference between reaching hundreds more patients or staying stuck in geographical constraints. The regulatory landscape for prescribing Schedule II stimulants via telemedicine has been a moving target since 2020, and the rules vary significantly by state and provider type.

Here’s what you actually need to know in 2026.

The Federal Baseline: Where We Stand Through 2026

The short answer: Yes, you can prescribe ADHD medications via telehealth through December 31, 2026—no initial in-person exam required.

The Ryan Haight Act of 2008 normally requires an in-person medical evaluation before prescribing any controlled substance. That was the law for over a decade. COVID changed everything. In March 2020, the DEA waived that requirement for prescribing Schedule II–V controlled substances via telehealth, as long as the provider conducted a legitimate evaluation via live audio-visual communication.

That waiver has been extended four times. As of January 2026, the flexibility runs through the end of 2026. This means a psychiatrist in California can start a new patient on Adderall after a video consultation. A PMHNP in Florida can initiate Vyvanse for an adult ADHD patient they’ve never met in person. Legally. Federally.

But there’s a catch—actually, several.

What the Current Rules Require

During this extension period, telehealth prescribing of ADHD medications must meet these conditions:

• Live video consultation: Audio-only doesn’t cut it for Schedule II stimulants (the DEA has only allowed audio-only for specific substance use disorder medications like buprenorphine). You need real-time, two-way audiovisual communication.
• Legitimate medical purpose: This isn’t a rubber-stamp operation. You need to conduct a thorough psychiatric evaluation that meets the standard of care—clinical interview, DSM-5-TR criteria verification, assessment of comorbidities, discussion of risks and benefits.
• Standard prescribing protocols: You still need a valid DEA registration, state medical license where the patient is located, and compliance with state PDMP (Prescription Drug Monitoring Program) requirements.
• E-prescribing: Most states now require electronic prescribing for all controlled substances. Paper prescriptions for Adderall are essentially obsolete.

This isn’t a free-for-all. The DEA has actively investigated telehealth companies for alleged over-prescription of stimulants. Your documentation needs to be airtight.

What’s Coming After 2026?

The DEA has previewed three new permanent rules that will replace the temporary extensions, likely taking effect in 2027. Key elements for ADHD providers:

1. Telemedicine Special Registration
The DEA will create a pathway for providers to obtain a special registration authorizing telehealth prescribing of controlled substances without an in-person exam. This will likely require:

• Mandatory nationwide PDMP checks (the DEA is building a national data hub)
• Strict patient identity verification during video consults
• Additional compliance safeguards

2. Established Patient Exception
If you’ve seen a patient in person at least once (or another provider in your practice has), the new telehealth restrictions won’t apply. You can continue treating them remotely.

3. Corporate Oversight
For the first time, telehealth platforms (not just individual providers) will need DEA registration. This suggests agency-level accountability to prevent ‘pill mill’ behavior.

The bottom line: telehealth ADHD prescribing isn’t going away, but it will likely require additional registration and compliance steps. Stay prepared.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Rules: Where It Gets Complicated

Federal law sets the floor, but your state can add requirements. And for ADHD prescribing, the differences matter—especially if you’re a nurse practitioner.

California: Permissive and Getting More So

California doesn’t require an in-person exam beyond federal rules. The state explicitly allows telehealth evaluations to satisfy prescribing standards. California Business & Professions Code §2242 defines ‘appropriate prior examination’ to include telehealth encounters—even asynchronous methods in some cases, though for controlled substances you’d want live video.

What you need:

• Full California medical license (no IMLC; no telehealth registration shortcut)
• CURES PDMP check before initial Schedule II prescription and every 4 months for ongoing therapy (mandatory)
• Standard of care documentation

NP Scope:
California is transitioning to Full Practice Authority for nurse practitioners. As of 2026, experienced PMHNPs (who’ve completed 3 years or 4,600 hours under physician oversight) can practice and prescribe stimulants independently. New grad NPs still need supervising agreements initially.

This is significant: by 2026, a California PMHNP can operate a fully independent telehealth ADHD practice without physician oversight. That’s rare nationally.

Texas: Physicians Only for Stimulants

Texas allows telemedicine for mental health treatment. Psychiatrists (MD/DO) can prescribe ADHD medications via telehealth without restrictions, beyond standard prescribing protocols.

Here’s the problem: Texas law prohibits nurse practitioners and physician assistants from prescribing Schedule II controlled substances to outpatients. Period.

The only exceptions are inpatient hospital orders (≥24 hours), hospice care, or emergency department orders. Outpatient ADHD treatment doesn’t qualify. Texas Board of Nursing guidance is explicit: ‘There are no other outpatient settings at which APRNs may prescribe Schedule II controlled substances.’

What this means practically:
If you’re building a telehealth ADHD practice in Texas, you need physicians. An NP can evaluate patients, manage therapy sessions, coordinate care—but a psychiatrist must write the Adderall prescription. You can structure collaborative models, but the MD/DO must be in the loop.

Texas NPs can prescribe Schedule III–V (like certain ADHD non-stimulants), but for Adderall, Vyvanse, Ritalin—the medications most ADHD patients need—you need a physician.

PDMP Requirement:
Texas mandates PDMP checks for opioids, benzodiazepines, barbiturates, and carisoprodol. Interestingly, stimulants aren’t on that mandatory list. Still, checking the Texas PMP for any ADHD patient is best practice (and good liability protection).

Florida: Explicit Carve-Out for Psychiatric Treatment

Florida has one of the clearest telehealth laws for ADHD. Florida Statutes §456.47 generally prohibits prescribing Schedule II controlled substances via telehealth—except for:

1. Treatment of a psychiatric disorder
2. Inpatient hospital treatment
3. Hospice care
4. Nursing home resident care

ADHD is a psychiatric disorder. So Florida explicitly allows telehealth prescribing of stimulants for ADHD without an in-person visit.

Out-of-State Providers:
Florida created a telehealth registration system for out-of-state providers. A psychiatrist licensed in another state can register with Florida’s Department of Health to legally provide telehealth services to Florida patients—including prescribing ADHD medications under the psychiatric exception. You’ll need:

• Active, unrestricted license in your home state
• Clean disciplinary record (5 years)
• Malpractice insurance
• Registration with Florida’s PDMP (E-FORCSE)

This is a huge advantage for telehealth platforms recruiting providers.

NP Scope:
Florida PMHNPs can prescribe stimulants, but they must work under a protocol agreement with a supervising psychiatrist. The 2017 law allowing APRNs to prescribe controlled substances included a 7-day supply limit for Schedule II—unless the APRN is a ‘psychiatric nurse’ prescribing for a mental disorder. Qualified PMHNPs (advanced degree in psychiatric nursing + 2 years post-grad psych experience under a psychiatrist) aren’t subject to the 7-day limit.

But they still need physician supervision. Florida’s 2020 independence law for APRNs excluded psychiatric NPs.

PDMP Requirement:
Florida requires E-FORCSE checks before prescribing controlled substances to patients 16 or older (with limited exceptions like non-refillable 3-day supplies).

New York: Recently Aligned with Federal Rules

Until May 2025, New York had its own restriction mirroring the Ryan Haight Act. The state updated its regulations (effective May 21, 2025) to explicitly allow prescribing controlled substances via telehealth consistent with federal law.

Translation: As long as the federal extension is in place, telehealth ADHD prescribing is legal in New York.

What you need:

• New York medical license (no IMLC; no telehealth shortcuts)
• I-STOP/PMP registry check before prescribing any Schedule II, III, or IV controlled substance (mandatory)
• Electronic prescribing (New York mandated e-prescribing for all controlled substances since 2016)

NP Scope:
New York is NP-friendly. After 3,600 hours of practice, PMHNPs can practice independently without a written collaborative agreement (though they must have a defined collaborative relationship with a physician). New York NPs can prescribe Schedule II–V with no state-specific quantity limits.

Unique Advantage:
New York allows up to a 90-day supply of stimulants for ADHD if the prescription indicates it’s for ADHD (by assigning condition code ‘B’). This applies to both physicians and NPs. For stable telehealth patients, this dramatically reduces refill hassle.

Pennsylvania: Collaboration Required for NPs

Pennsylvania permits telemedicine broadly and doesn’t impose state-specific barriers to controlled substance prescribing beyond federal law. The state’s medical boards confirmed that a valid provider-patient relationship can be established via telemedicine.

What you need:

• Pennsylvania medical license (or IMLC for physicians—PA joined the compact in 2022)
• PA PDMP check before initial prescription of any controlled substance in a new course of treatment (required by law for opioids/benzos; advisable for stimulants)
• E-prescribing (mandatory since 2019)

NP Scope:
Pennsylvania is a restricted practice state. CRNPs must have a collaborative agreement with a physician to practice and prescribe. For Schedule II controlled substances, Pennsylvania regulation limits CRNPs to a 30-day supply. Any continuation beyond 30 days requires physician approval.

This doesn’t mean the patient must see the physician—it means the NP needs to communicate with their collaborating psychiatrist before month two. The physician must also conduct monthly chart reviews of the NP’s Schedule II prescribing.

Practical Implication:
If you’re an NP in Pennsylvania treating ADHD via telehealth, structure your practice with a supervising psychiatrist who can review your cases monthly. If you’re a platform, you need Pennsylvania psychiatrists on staff to support NPs.

Illinois: Two-Tiered System for NPs

Illinois allows telehealth for controlled substance prescribing with no state-imposed barriers beyond federal rules. The Illinois Telehealth Act (updated 2021) ensures parity.

What you need:

• Illinois medical license + Illinois Controlled Substance License (separate credential required for all prescribers)
• IL PMP check recommended for initial ADHD prescriptions (mandatory for opioids; advisable for due diligence on stimulants)

NP Scope—This Gets Interesting:
Illinois created a pathway for APRNs to achieve Full Practice Authority. After completing 4,000 hours of clinical practice under a collaborative agreement + 250 hours of continuing education, an Illinois NP can apply for an ‘Illinois FPA APRN’ license.

Without FPA: NPs work under a collaborative agreement with a physician. For Schedule II substances, they’re limited to a 30-day supply and must obtain physician approval for any continuation.

With FPA: NPs can prescribe independently, including Schedule II–V controlled substances. Here’s the nuance: Illinois law requires FPA NPs to have a ‘consultation relationship’ with a physician specifically for Schedule II narcotic drugs (opioid analgesics) and benzodiazepines.

But ADHD stimulants are Schedule II non-narcotic controlled substances. The law doesn’t mandate a consultation relationship for stimulants. An Illinois FPA-certified PMHNP can prescribe Adderall independently via telehealth without physician oversight.

This is a significant opportunity for experienced NPs.

Other Note:
Illinois allows ‘Prescribing Psychologists’ with advanced training and physician collaboration to prescribe psychotropic medications—but they’re excluded from prescribing Schedule II substances. ADHD medication management remains with MDs, DOs, NPs, and PAs.

State-by-State Summary Table

What This Means for Your Practice

If You’re a Psychiatrist (MD/DO)

You have full prescribing authority in every state. The barriers for you are purely logistical:

• Licensure: You need a medical license in every state where your patients are located. IMLC membership (available in 40+ states including Pennsylvania and Texas, but not California, New York, or Florida) can expedite multi-state licensing.
• DEA Registration: Your DEA registration must cover each state you practice in.
• PDMP Compliance: Learn the requirements for each state. Some mandate checks for every controlled prescription (New York). Others focus on opioids but expect due diligence for stimulants (Texas, Pennsylvania).

Economics:
Traditional outpatient psychiatry limits you to your geographical area and the patients who can physically reach your office. Telehealth removes that constraint. The demand for ADHD treatment vastly exceeds supply—especially for providers who take insurance.

But here’s the reality of patient acquisition: building a telehealth practice through DIY marketing (SEO, Google Ads, directory listings) typically costs $200–500+ per acquired patient when you factor in all expenses:

• Agency/consultant fees
• Ad spend testing and optimization
• Staff time to handle and qualify leads
• No-show rates from cold leads
• Months of SEO investment before meaningful results
• Failed campaigns

SEO takes 6–12 months of consistent investment before generating patient flow. Google Ads for mental health keywords run $15–40+ per click, and most clicks don’t convert. Psychology Today and Zocdoc charge monthly fees and per-booking fees, and you’re competing with hundreds of other providers.

A platform like Klarity Health offers a different model: pay per appointment booked (similar to Zocdoc), but with pre-qualified patients already matched to your specialty and availability. No upfront marketing spend. No monthly subscription gambling on whether your SEO will work. You pay only when a patient actually books with you—guaranteed ROI vs. marketing risk.

If You’re a Psychiatric Nurse Practitioner

Your scope depends entirely on your state. Here’s the strategic breakdown:

Unrestricted States (CA, NY, IL with FPA):
You can build a fully independent telehealth ADHD practice. In California by 2026, after meeting experience requirements, you’re autonomous. In New York, after 3,600 hours, you can prescribe without a collaborative agreement. In Illinois with FPA, you can prescribe stimulants independently.

These states offer the best opportunity for NP-led telehealth practices. You can scale without physician bottlenecks.

Collaborative States (FL, PA, IL without FPA):
You can treat ADHD patients via telehealth, but you need a supervising psychiatrist in the loop. In Pennsylvania and Illinois (non-FPA), that means physician approval after the initial 30-day prescription. In Florida, you need a protocol agreement.

This isn’t necessarily a barrier—it’s a practice structure decision. Many successful telehealth ADHD practices use a collaborative model where NPs handle the patient relationship and ongoing management, with psychiatrists providing oversight and handling complex cases.

Prohibited States (TX):
Texas is currently a non-starter for NP-led ADHD medication management. You can evaluate and provide therapy, but a physician must prescribe the stimulants. If you’re an NP considering telehealth in Texas, you need to partner with a psychiatrist or join a platform with physicians on staff.

Compliance Checklist: What You Can’t Miss

Regardless of your state, these are non-negotiable:

1. PDMP Checks

Almost every state requires or strongly expects PDMP review before prescribing controlled substances. For ADHD medications:

• Check before the initial prescription
• Check periodically (quarterly is common)
• Document that you reviewed it and found no concerning patterns

This protects you from inadvertently prescribing to someone already getting stimulants from multiple providers (a red flag for diversion).

2. Thorough Documentation

Your telehealth evaluation must meet the same standard of care as in-person. Document:

• Full psychiatric history and ADHD symptom assessment
• DSM-5-TR criteria verification (at least 5 symptoms in two domains for adults; 6 for children)
• Review of prior diagnoses, if any
• Discussion of medication risks, benefits, and alternatives
• Assessment for contraindications (cardiovascular issues, substance use history, etc.)
• Evidence that the patient (or guardian for minors) consented to telehealth treatment

If audited or questioned, ‘I did a video call’ isn’t sufficient. Your documentation needs to show you conducted a legitimate psychiatric evaluation.

3. E-Prescribing

Paper prescriptions for controlled substances are obsolete in most states. Ensure your EHR/prescribing system is set up for EPCS (Electronic Prescribing of Controlled Substances) with two-factor authentication.

4. Informed Consent

While not always legally mandated, obtaining and documenting patient consent for telehealth is best practice. Explain:

• How telehealth works
• Privacy protections (HIPAA compliance)
• Limitations (you can’t physically examine them)
• Emergency protocols (what they should do in a crisis)

For minors, ensure parent/guardian consent and involvement.

5. Stay Current on DEA Rules

The regulatory landscape is shifting. Subscribe to DEA updates, join professional associations (APA, AANP), and monitor state medical board guidance. When the DEA finalizes its telemedicine special registration rules in 2027, you’ll need to act quickly to maintain uninterrupted prescribing authority.

Frequently Asked Questions

Can I prescribe ADHD medication after just one telehealth visit?

Yes, under current federal rules (through 2026), you can prescribe Schedule II stimulants after an initial telehealth evaluation via live video, as long as it meets the standard of care. You don’t need an in-person visit first.

However, proper diagnosis and prescribing requires a thorough evaluation. If you can’t confidently diagnose ADHD and rule out contraindications via a single video consultation, schedule follow-up visits before prescribing.

Do I need to see telehealth ADHD patients in person eventually?

Not under current federal rules through 2026. If you’ve never seen a patient in person, watch for the DEA’s permanent rules (expected 2027), which may require either an in-person visit or a telemedicine special registration for ongoing prescribing.

Some states have no in-person requirement even post-federal rules (California, Florida for psychiatric treatment). Others may impose their own standards.

Can I prescribe controlled substances via audio-only (phone) visits for ADHD?

No. The DEA’s telehealth flexibilities for Schedule II substances require live, two-way audiovisual (video) communication. Audio-only is not sufficient for prescribing stimulants.

The DEA has allowed audio-only for certain buprenorphine prescriptions for opioid use disorder in limited circumstances, but that exception doesn’t extend to ADHD medications.

What if my patient moves to another state?

You must be licensed in the state where the patient is physically located at the time of the telehealth visit. If your patient moves, you need a license in their new state to continue prescribing.

Some providers use IMLC (Interstate Medical Licensure Compact) to expedite multi-state licensing. NPs should check if their state participates in the Nurse Licensure Compact (though this only covers RN licenses; APRN practice authority is state-specific).

How do I handle prior authorizations for ADHD medications via telehealth?

The same way you would in person. Many insurance plans require prior authorization for brand-name stimulants or higher doses. This is a payer issue, not a telehealth regulation issue.

Platforms like Klarity Health often have staff to handle prior authorization paperwork, which removes this administrative burden from providers. If you’re practicing independently, budget time for PA submissions or hire support staff.

Are there quantity limits on stimulant prescriptions via telehealth?

Federal law allows up to a 90-day supply of controlled substances if clinically appropriate. Most states align with this, though some impose shorter limits:

• Pennsylvania and Illinois (non-FPA NPs): 30-day limit on NP prescriptions of Schedule II (physician must approve continuation)
• New York: 90-day supply allowed for ADHD if prescription is coded appropriately

For telehealth, most providers initially prescribe 30-day supplies to monitor tolerance and response, then extend to 90 days for stable patients (if allowed by state law).

Can psychologists prescribe ADHD medications via telehealth?

In most states, no. Psychologists cannot prescribe any medications. A few states (Louisiana, New Mexico, Illinois, Idaho, Iowa) have ‘prescribing psychologist’ programs that allow specially trained psychologists with physician collaboration to prescribe psychotropic medications. However, Illinois explicitly excludes Schedule II substances from prescribing psychologists’ formulary—so no ADHD stimulants.

For ADHD medication management, you need a physician (MD/DO), nurse practitioner, or physician assistant (in states where their scope allows).

What happens if the DEA telemedicine rules change mid-treatment?

The DEA has indicated that established patients (those already under your care) will be grandfathered in under new rules. If you’ve been treating a patient via telehealth before any new in-person exam requirement kicks in, you can likely continue that relationship.

However, new patients after the rule change would need to meet the new requirements (likely obtaining a telemedicine special registration or conducting an in-person exam).

Stay informed so you’re not caught off-guard when new rules publish.

Why This Matters for Joining a Telehealth Platform

Building a solo telehealth ADHD practice is possible—but it’s expensive and time-consuming. You’re spending $3,000–5,000/month on marketing with uncertain results, navigating multi-state licensing, handling your own PDMP checks and e-prescribing setup, managing patient acquisition, dealing with no-shows from unqualified leads, and hoping your SEO investment pays off in 6–12 months.

Or you join a platform like Klarity Health that handles:

• Patient acquisition: Pre-qualified patients matched to your specialty and availability
• Compliance infrastructure: Built-in PDMP integration, e-prescribing, documentation templates that meet regulatory standards
• Multi-state licensing support: Guidance on which states to prioritize and IMLC/compact participation
• Both insurance and cash-pay flow: Patients already credentialed and ready to book
• No upfront costs: You pay a standard listing fee per new patient lead—only when you actually see patients

The economic case is clear: instead of gambling thousands on marketing channels that might work, you pay only for results. Guaranteed ROI. Your time goes to treating patients, not figuring out Google Ads optimization or calling insurance companies about credentialing.

And critically, platforms monitor regulatory changes for you. When the DEA publishes new telemedicine rules in 2027, Klarity providers will get clear guidance on what to do—no scrambling to interpret federal register documents on your own.

The Bottom Line

You can prescribe ADHD medications via telehealth legally and ethically through 2026 under federal rules—and likely beyond with appropriate registration. The state-level variation matters primarily for nurse practitioners (who face different prescribing authority depending on location) and for PDMP compliance details.

But the real question isn’t ‘Is it legal?’ It’s ‘How do I build a sustainable, compliant telehealth practice that actually reaches the patients who need ADHD treatment?’

The demand is massive. The regulations, while complex, are navigable. The economics favor platforms that remove patient acquisition risk.

If you’re a psychiatrist or PMHNP looking to expand your practice, treat more patients, and increase your income without the overhead of traditional practice—telehealth ADHD care is one of the highest-demand, most underserved markets in psychiatry.

Ready to see how Klarity Health handles the patient acquisition, compliance, and infrastructure so you can focus on treatment? Explore joining Klarity’s provider network and start seeing pre-qualified ADHD patients this month—no marketing spend, no multi-month SEO wait, just patients ready to book with you.

Citations and Sources

The regulatory information in this guide is current as of February 2026 and sourced from official government publications, state statutes, and verified regulatory guidance. Below are the primary sources consulted:

1. DEA & HHS Joint Press Release – Extension of Telemedicine Flexibilities Through December 31, 2026 (January 2, 2026). U.S. Department of Health and Human Services. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Healthcare Dive – DEA, HHS extend telehealth controlled substance prescribing flexibilities for fourth time (January 5, 2026). Emily Olsen. https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/

3. DEA Press Release – DEA Announces Three New Telemedicine Rules to Continue Open Access (January 16, 2025). U.S. Drug Enforcement Administration. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

4. Texas Board of Nursing – APRN Frequently Asked Questions: Practice (Current as of 2025). Texas Board of Nursing. https://www.bon.texas.gov/faqpracticeaprn.asp.html

5. Florida Statutes §456.47 – Telehealth (2019, current through 2025). Florida Legislature. https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

This content is for informational purposes and does not constitute legal advice. Providers should consult their state medical boards, legal counsel, and professional associations for guidance specific to their practice. Regulations are subject to change.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care